China biopharmaceutical's first three quarters financial report is out! R & D cost over 2 billion

On November 26, China biopharmaceutical announced its results for the first three quarters of 2019, with revenue of 19.32 billion yuan, up 22.8% year on year Among them, liver disease drugs accounted for 25.7% of the group's revenue, up to 4.966 billion yuan; tumor drugs accounted for 21.8% of the group's revenue, up to 4.202 billion yuan; cardiovascular and cerebrovascular drugs accounted for 12.9% of the group's revenue, up to 2.495 billion yuan The sales volume of analgesic drugs was 1.652 billion yuan, accounting for 8.6% of the group's revenue China's R & D investment in the first three quarters of Biopharmaceutics reached 2.054 billion yuan (accounting for 10.6% of the group's revenue) The sales volume of tumor drugs is about 4.202 billion yuan, accounting for 21.8% of the group's revenue Although its heavyweight original antitumor drug, androtinib, did not disclose specific sales, according to its published data of other varieties, its sales in the first three quarters are estimated to exceed 2.5 billion.